Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Kyowa Hakko returns to Geron Asian rights to telomerase inhibitors

July 5, 2004

Point Therapeutics commences last planned phase II studies for talabostat

July 5, 2004

CF-101 enters phase I study in solid tumor patients

July 5, 2004

PXD-101 enters phase I trial in hematologic cancer

July 2, 2004

Erbitux receives E.U. approval for metastatic colorectal cancer

July 2, 2004

Femara sNDA granted priority review by FDA

July 2, 2004

New IGF-1R inhibitors with potential in cancer therapy

July 2, 2004

Novel topoisomerase inhibitors identified by researchers at State U. of New Jersey

July 2, 2004

Retinoic metabolism inhibitors promising against prostate cancer

July 2, 2004

Exelixis submits IND for XL-999

July 2, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...